Sentences with phrase «pembrolizumab shows»
The combination of the attenuated oncolytic virus talimogene laherparepvec (T - VEC) and the immune checkpoint inhibitor pembrolizumab shows activity and is well tolerated by advanced melanoma patients, according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18 — 21 in San Francisco.
http://www.cancernetwork.com/
May 29, 2015 Pembrolizumab shows real promise against head and neck cancer Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda ®) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology (ASCO).
«Pembrolizumab shows promise in treatment of mesothelioma.»
«Immunotherapy drug effective for metastatic triple negative breast cancer: Pembrolizumab shown to shrink tumors — regardless of whether patient had prior treatment.»
Not exact matches
The idea to specifically study this group of patients was based on groundbreaking research Garon published in the New England Journal of Medicine last year, which found that among patients who received pembrolizumab, those with PD - L1 expression on at least 50 percent of their cancer cells showed the longest survival and disease control.
«The data show that treatment with pembrolizumab and chemotherapy together is more effective than chemotherapy alone,» says Gandhi.
Dr Butler said: «Our results show that patients benefited from pembrolizumab regardless of whether or not they had been pre-treated with ipilimumab.»
Clinical trials of a new immunotherapy, pembrolizumab, have shown that it prolongs life significantly for patients with bladder cancer and is active against a rare sub-type of melanoma, called mucosal melanoma.
It represents a real advance in the second - line treatment of advanced bladder cancer because pembrolizumab is the first therapy to show a significant survival advantage over chemotherapy for these patients.
But here Butler and colleagues pull three trials together and show that long - lasting responses also occur with pembrolizumab in patients with mucosal melanoma.»
Pembrolizumab has also shown promise for patients with metastatic triple - negative breast cancer (mTNBC).
Pembrolizumab, which has already been shown safe and effective as monotherapy for advanced, non-squamous non-small cell lung cancer (NSCLC), might also be an effective component in combination therapy for the disease.
At the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, we presented monotherapy data of nine patients who received G100 with radiation (no pembrolizumab) that showed 100 % DCR rate, with 44 % of the patients achieved a partial response (PR) based on WHO criteria, which requires at least a 50 % tumor reduction to qualify as a PR.